TABLE 2

Tissue Distribution at 4, 24, and 48 Hours After Injection

Tissue	Time after injection (h)
		4					24			48
		¹¹¹ln-DOTA-MSH_oct	¹¹¹ln-DOTA-NAPamide	⁶⁷Ga-DOTA-NAPamide	¹¹¹ln-DOTA-NAPamide	⁶⁷Ga-DOTA-NAPamide	¹¹¹ln-DOTA-NAPamide	⁶⁷Ga-DOTA-NAPamide
Blood	0.03 ± 0.00*	0.12 ± 0.01	0.26 ± 0.03*	0.01 ± 0.00	0.06 ± 0.01^†	0.00 ± 0.00	0.02 ± 0.00
Muscle	0.03 ± 0.01	0.05 ± 0.01	0.05 ± 0.01	0.01 ± 0.00	0.02 ± 0.00	0.01 ± 0.00	0.02 ± 0.00
Liver	0.41 ± 0.02	0.43 ± 0.04	0.28 ± 0.02*	0.30 ± 0.02	0.25 ± 0.02	0.23 ± 0.00	0.23 ± 0.02
Kidney	13.5 ± 1.12*	5.06 ± 0.32	3.98 ± 0.10	2.65 ± 0.36	2.04 ± 0.17	1.46 ± 0.08	1.24 ± 0.09
Spleen	0.15 ± 0.01	0.15 ± 0.01	0.17 ± 0.02	0.10 ± 0.01	0.14 ± 10.01	0.11 ± 0.01	0.15 ± 0.02
Lung	0.10 ± 0.01	0.09 ± 0.01	0.20 ± 0.03*	0.05 ± 0.01	0.09 ± 0.01	0.03 ± 0.00	0.06 ± 0.01
Small intestine	0.11 ± 0.03	0.07 ± 0.01	0.16 ± 0.02^‡	0.04 ± 0.00	0.13 ± 0.02^‡	0.03 ± 0.00	0.12 ± 0.02^‡
Heart	0.03 ± 0.00	0.05 ± 0.01	0.09 ± 0.01*	0.03 ± 0.01	0.03 ± 0.00	0.02 ± 0.00	0.03 ± 0.00
Bone	0.08 ± 0.01	0.13 ± 0.03	0.36 ± 0.05*	0.18 ± 0.04	0.28 ± 0.03	0.04 ± 0.01	0.27 ± 0.04*
Pancreas	0.03 ± 0.00	0.04 ± 0.00	0.09 ± 0.01*	0.02 ± 0.00	0.06 ± 0.01*	0.02 ± 0.00	0.05 ± 0.01^‡
Skin	0.10 ± 0.02^†	0.18 ± 0.04	0.19 ± 0.02	0.05 ± 0.01	0.11 ± 0.02	0.07 ± 0.01	0.08 ± 0.01
Stomach	0.10 ± 0.02	0.09 ± 0.02	0.11 ± 0.01	0.08 ± 0.01	0.11 ± 0.01	0.05 ± 0.01	0.15 ± 0.05
Tumor	4.31 ± 0.30*	7.56 ± 0.51	9.43 ± 1.06^†	2.32 ± 0.28	3.10 ± 0.36	1.16 ± 0.06	1.61 ± 0.20

↵* P < 0.001 vs. ¹¹¹ln-DOTA-NAPamide.
↵^† P < 0.05 vs. ¹¹¹ln-DOTA-NAPamide.
↵^‡ P < 0.01 vs. ¹¹¹ln-DOTA-NAPamide.
¹¹¹ln-DOTA-NAPamide, ⁶⁷Ga-DOTA-NAPamide, or ¹¹¹ln-DOTA-MSH_oct as reference compound was injected to melanoma-bearing mice and tissue-associated radioactivity was measured 4, 24, and 48 h after injection. Results are expressed as %ID/g (mean ± SEM; n = 4–8).